About ALX Oncology Holdings Inc.
https://www.alxoncology.comALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer.
CEO
Jason W. Lettmann
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 15
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
UBS
Buy
HC Wainwright & Co.
Buy
Jefferies
Buy
Piper Sandler
Overweight
Cantor Fitzgerald
Overweight
Stifel
Hold
Grade Summary
Showing Top 6 of 6
Price Target
Institutional Ownership
VENBIO PARTNERS LLC
Shares:9.7M
Value:$12.9M
REDMILE GROUP, LLC
Shares:3.33M
Value:$4.43M
BLACKROCK INC.
Shares:2.69M
Value:$3.57M
Summary
Showing Top 3 of 73
About ALX Oncology Holdings Inc.
https://www.alxoncology.comALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $22.53M ▼ | $-22.14M ▲ | 0% | $-0.41 ▲ | $-21.58M ▲ |
| Q2-2025 | $0 | $26.65M ▼ | $-25.95M ▲ | 0% | $-0.49 ▲ | $-25.35M ▲ |
| Q1-2025 | $0 | $31.82M ▲ | $-30.75M ▼ | 0% | $-0.58 ▼ | $-30.14M ▼ |
| Q4-2024 | $0 | $30.61M ▼ | $-29.16M ▲ | 0% | $-0.55 ▲ | $-28.52M ▲ |
| Q3-2024 | $0 | $32.57M | $-30.71M | 0% | $-0.58 | $-30.04M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $60.63M ▼ | $82.72M ▼ | $37.92M ▲ | $44.8M ▼ |
| Q2-2025 | $79.31M ▼ | $95.32M ▼ | $30.91M ▼ | $64.42M ▼ |
| Q1-2025 | $97.83M ▼ | $120.9M ▼ | $32.6M ▼ | $88.3M ▼ |
| Q4-2024 | $127.76M ▼ | $147.78M ▼ | $34.16M ▼ | $113.62M ▼ |
| Q3-2024 | $148.57M | $185.72M | $48.91M | $136.81M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-22.14M ▲ | $-17.09M ▲ | $21.39M ▼ | $-159K ▲ | $4.14M ▲ | $-17.15M ▲ |
| Q2-2025 | $-25.95M ▲ | $-23.41M ▲ | $22.32M ▼ | $-222K ▼ | $-1.31M ▼ | $-23.45M ▲ |
| Q1-2025 | $-30.75M ▼ | $-24.66M ▲ | $27.64M ▼ | $65K ▼ | $3.05M ▲ | $-24.72M ▲ |
| Q4-2024 | $-29.16M ▲ | $-32.05M ▼ | $33.18M ▲ | $328K ▲ | $1.47M ▲ | $-32.11M ▼ |
| Q3-2024 | $-30.71M | $-25.38M | $25.69M | $251K | $568K | $-25.52M |
CEO
Jason W. Lettmann
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 15
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
UBS
Buy
HC Wainwright & Co.
Buy
Jefferies
Buy
Piper Sandler
Overweight
Cantor Fitzgerald
Overweight
Stifel
Hold
Grade Summary
Showing Top 6 of 6
Price Target
Institutional Ownership
VENBIO PARTNERS LLC
Shares:9.7M
Value:$12.9M
REDMILE GROUP, LLC
Shares:3.33M
Value:$4.43M
BLACKROCK INC.
Shares:2.69M
Value:$3.57M
Summary
Showing Top 3 of 73